Short answer
Septerna, Inc. (SEPN) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (down 12.2% year over year) with net income of −$27M.
Q3 2026 key financials · XBRL
- Revenue
- $19M
- −12.2% YoY · −29.4% QoQ
- Net income
- −$27M
- −425.3% YoY · −104.0% QoQ
- Operating margin
- -144.2%
- EPS (diluted)
- −$0.58
- −405.3% YoY · −100.0% QoQ
Source: XBRL data from the Septerna, Inc. (SEPN) Q3 2026 10-Q on SEC EDGAR. USD.
Septerna, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $18.9M, down $2.6M YoY from $21.5M, including $13.2M cumulative catch-up reduction
- Net loss $26.6M vs $8.2M net income YoY, operating loss $27.2M vs $2.6M income
- R&D spending $36.6M, up $12.3M YoY, led by other discovery/preclinical programs at $7.2M
- Cash, equivalents and marketable securities $565.2M, funding operations into mid-2029
- ATM proceeds $61.0M; operating cash use $61.6M through nine months, SEP-479 data expected first quarter 2027
Risk Factors
- Newly added development risk: SEP-204 selected as a development candidate in November 2026, expanding preclinical execution demands
- Regulatory risk: June 2026 FDA draft guidance permits one pivotal trial with confirmatory evidence, but FDA may still require a second trial
- Clinical safety risk: SEP-786 discontinued after two unanticipated Grade 3 elevated unconjugated bilirubin events
- Financial risk: $565.2 million in cash, equivalents and marketable securities expected to fund operations into mid-2029
- Trade and supply-chain risk: BIOSECURE Act restrictions could disrupt reliance on China-based CDMOs, including WuXi
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Septerna, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.